Biography
Dr. Zhang is a bioinformatician and native of China. He has been trained in both cell biology and computer science and has extensive experience in genomic analysis. His current research focuses on development and implementation of bioinformatics tools/pipeline in high throughput genomic analysis of research and clinical specimen.
He serves as the Bioinformatics Director and is the key person in genomic data analysis of Electronic Medican Records (EMR) - linked specimens in Biobank of the Institute of Personalized Medicine (IPM).
Zhang Laboratory
Research
Dr. Zhang is a Co-investigator of the NHGRI-funded U01 grant ‘Biorepositories for Genomic Medicine in Diverse Communities’, and is responsible for SNP and sequencing data analysis for projects of the National Human Genome Research Institute's ‘Electronic Medical Records and Genomics’ (eMERGE) II Network at MSSM. He is also a subcontract site - Principal Investigator of several National Institutes of Health funded projects including ' The Pathogenesis of HIV-Associated Nephropathy', ' Targeting Renal Inflammatory Pathways of SLE Nephritis in Mouse and Man' and ' DIaT as a transcriptional regulator of non-replicating Mycobacterium tuberculosis'.
Research Interests:
- Integrative analysis of candidate SNPs from genome-wide association analysis study of human complex diseases
- Algorithm and pipeline development of deep-sequencing analysis
- Genomics aberration study in cancer and hematological malignancies
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Zhang did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.